GENENTECH, INC for GENENTECH INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Issues Comparative Effectiveness S. 301 Physician Payments Sunshine Act of 2009 Oncology Quality Care Improvement Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| WALTER MOORE | — |
| PETER JOSEPH MULLER | — |
| HEIDI L WAGNER | — |
Budget/Appropriations BUD
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85 Comparative Effectiveness
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| WALTER MOORE | — |
| PETER JOSEPH MULLER | — |
| HEIDI L WAGNER | — |
Pharmacy PHA
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act of 2009 S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| WALTER MOORE | — |
| PETER JOSEPH MULLER | — |
| HEIDI L WAGNER | — |
Copyright/Patent/Trademark CPT
H.R. 1260 Patent Reform S. 515 Patent Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| WALTER MOORE | — |
| PETER JOSEPH MULLER | — |
| HEIDI L WAGNER | — |
Medical/Disease Research/Clinical Labs MED
LHHS Appropriations (CMS and comparative effectiveness related matters)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| WALTER MOORE | — |
| PETER JOSEPH MULLER | — |
| HEIDI L WAGNER | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ROCHE HOLDING, LTD | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.